by Kevin Dooley, MD | Aug 14, 2026 | News and Information
Abcuro has raised $66 million to move ulviprubart (ABC008) into a new Phase 3 clinical trial in inclusion body myositis (IBM). The company plans to begin the study later this year and will focus on people with less severe IBM. Abcuro CEO Alex Martin told Endpoints... 
by Kevin Dooley, MD | Jun 12, 2026 | News and Information, Research News
Cure IBM has been informed by Abcuro that the company has made the decision to close ABC008-IBM-202, the open-label long-term extension study of ulviprubart in people with inclusion body myositis. This means that patients in the extension study will no longer have... 
by Kevin Dooley, MD | Mar 18, 2026 | News and Information
A newly published study on pioglitazone in inclusion body myositis gives reason for cautious optimism, although the study was small and preliminary. The main goal was not to learn whether pioglitazone is effective in treating IBM, but to see if it could shift... 
by Kevin Dooley, MD | Feb 24, 2026 | News and Information
Abcuro announced results today from its Phase 2/3 MUSCLE trial of ulviprubart (ABC008) in inclusion body myositis (IBM). In the full trial population, the study did not meet its main goal or key secondary goals. The main goal was change in IBM Functional Rating Scale... 
by Kevin Dooley, MD | Apr 30, 2024 | News and Information
Who Can Participate in the Survey? The international COVAD study team, led by Dr. Latika Gupta, is studying the subjective well-being of people living with autoimmune diseases, including inclusion body myositis (IBM). This is an important topic, since disabling...
